



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Robert M David, Ph.D

PATIENT

DEMOGRAPHICS

Patient Name: JOSEPH MONTGOMERY	Account: Desert Kidney Associates Chandler	Order Code: NE22-0007288
DOB: 04/15/1952	Provider: Mashood Qadri	Sample Type: Urine
Patient Gender: M	Accession: 22040700033	Collected: 04/06/2022
Patient Phone Number: (480) 415-8737	Report Status: FINAL	Received: 2022-04-07T14:19:03.500702
		Reported: 04/13/2022

PRESCRIPTION

LIST

Duloxetine (Cymbalta) , Gabapentin (Neurontin) , Carvedilol (Coreg , Coreg CR) , Hydralazine (Apresoline) , Atorvastatin (Lipitor) , Tamsulosin (Flomax) , Glipizide (GLipIZIDE XL , Glucotrol XL , Glucotrol) , Sitagliptin (Januvia) , Clopidogrel (Plavix) , Verapamil (Calan , Verelan) , Allopurinol (Zyloprim , Aloprim) , Famotidine (Pepcid AC , Pepcid) , Fluorouracil (Efudex) , Fenofibrate (Antara , Fenoglide , Lipofen , TriCor , Triglide , Lipidil Micro , Dom-Fenofibrate , Lipidil Supra , Lofibra , Lipidil EZ)

DIAGNOSIS

CODES

Z51.81, Z79.899, N18.3 Chronic kidney disease, stage 3 unspecified, I10 Hypertension

INCONSISTENT				INCONSISTENT			
NOT PRESCRIBED		DETECTED		PRESCRIBED		NOT DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)	Class	Test	Cutoff (ng/mL)	
NSAID	Acetaminophen	400	> 20000	ANTIDIABETIC	Glipizide	10	
[DDI] Acetaminophen may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. [DDI] The metabolism of Fluorouracil can be decreased when combined with Acetaminophen. [DDI] Acetaminophen may decrease the excretion rate of Allopurinol which could result in a higher serum level. [DDI] Acetaminophen may decrease the excretion rate of Tamsulosin which could result in a higher serum level. [DDI] Carvedilol may increase the hepatotoxic activities of Acetaminophen. [DDI] The metabolism of Clopidogrel can be decreased when combined with Acetaminophen. [DDI] The metabolism of Acetaminophen can be decreased when combined with Famotidine. [DDI] Acetaminophen may decrease the excretion rate of Glipizide which could result in a higher serum level. [DDI] Acetaminophen may decrease the excretion rate of Hydralazine which could result in a higher serum level. [DDI] The metabolism of Atorvastatin can be decreased when combined with Acetaminophen. [DDI] Acetaminophen may decrease the excretion rate of Sitagliptin which could result in a higher serum level. [DDI] Acetaminophen may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. [DDI] The metabolism of Acetaminophen can be decreased when combined with Duloxetine. [DDI] The metabolism of Acetaminophen can be decreased when combined with Verapamil.				[DDI] Salicylic acid may increase the hypoglycemic activities of Glipizide. [DDI] The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Glipizide. [DDI] Glipizide may decrease the excretion rate of Hydralazine which could result in a higher serum level. [DDI] Sitagliptin may increase the hypoglycemic activities of Glipizide. [DDI] Allopurinol may decrease the excretion rate of Glipizide which could result in a higher serum level. [DDI] Glipizide may decrease the excretion rate of Atorvastatin which could result in a higher serum level. [DDI] The risk or severity of hypoglycemia can be increased when Fenofibric acid is combined with Glipizide. [DDI] The therapeutic efficacy of Glipizide can be increased when used in combination with Tamsulosin. [DDI] The therapeutic efficacy of Glipizide can be increased when used in combination with Carvedilol. [DDI] The metabolism of Glipizide can be decreased when combined with Clopidogrel. [DDI] The risk or severity of hypoglycemia can be increased when Verapamil is combined with Glipizide. [DDI] The metabolism of Glipizide can be decreased when combined with Fluorouracil.			
STIMULANT	Caffeine	50	1737.80				
[DDI] The risk or severity of adverse effects can be increased when Carvedilol is combined with Caffeine. [DDI] Gabapentin may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy. [DDI] The metabolism of Fluorouracil can be decreased when combined with Caffeine. [DDI] The metabolism of Clopidogrel can be decreased when combined with Caffeine. [DDI] The serum concentration of Caffeine can be increased when it is combined with Allopurinol. [DDI] The metabolism of Caffeine can be decreased when combined with Famotidine. [DDI] The metabolism of Verapamil can be decreased when combined with Caffeine.							
ANTI HISTAMINE	Diphenhydramine	50	231.75				
[DDI] The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Fluorouracil. [DDI] The metabolism of Tamsulosin can be decreased when combined with Diphenhydramine. [DDI] The metabolism of Diphenhydramine can be decreased when combined with Glipizide. [DDI] The risk or severity of QTc prolongation can be increased when Famotidine is combined with Diphenhydramine. [DDI] The metabolism of Diphenhydramine can be decreased when combined with Duloxetine. [DDI] The metabolism of Diphenhydramine can be decreased when combined with Salicylic acid. [DDI] The metabolism of Diphenhydramine can be decreased when combined with Fenofibrate. [DDI] The metabolism of Carvedilol can be decreased when combined with Diphenhydramine. [DDI] The metabolism of Diphenhydramine can be decreased when combined with Clopidogrel. [DDI] The metabolism of Diphenhydramine can be decreased when combined with Verapamil.							
NSAID	Salicylic Acid	400	2578.79				
Metabolite of Acetylsalicylic Acid [DDI] Salicylic acid may decrease the antihypertensive activities of Carvedilol. [DDI] Salicylic acid may decrease the antihypertensive activities of Hydralazine. [DDI] Salicylic acid may decrease the excretion rate of Tamsulosin which could result in a higher serum level. [DDI] The risk or severity of bleeding can be increased when Salicylic acid is combined with Clopidogrel. [DDI] The risk or severity of bleeding can be increased when Verapamil is combined with Salicylic acid. [DDI] The excretion of Allopurinol can be decreased when combined with Salicylic acid. [DDI] The excretion of Famotidine can be decreased when combined with Salicylic acid. [DDI] The metabolism of Salicylic acid can be decreased when combined with Fluorouracil.							

CONTRAINDICATION		NOT TESTED
Drug	Contraindication	
Carvedilol	[DDI] The metabolism of Carvedilol can be decreased when combined with Fenofibrate. [DDI] The metabolism of Carvedilol can be decreased when combined with Famotidine. [DDI] The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Carvedilol. [DDI] The metabolism of Carvedilol can be decreased when combined with Fluorouracil. [DDI] Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Carvedilol. [DDI] Carvedilol may increase the hypotensive activities of Hydralazine.	
Hydralazine	[DDI] Hydralazine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. [DDI] The risk or severity of adverse effects can be increased when Tamsulosin is combined with Hydralazine.	
Tamsulosin	[DDI] Tamsulosin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.	
Allopurinol	[DDI] Allopurinol may decrease the excretion rate of Hydralazine which could result in a higher serum level. [DDI] Allopurinol may decrease the excretion rate of Tamsulosin which could result in a higher serum level. [DDI] Allopurinol may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.	
Famotidine	[DDI] The excretion of Allopurinol can be decreased when combined with Famotidine. [DDI] The metabolism of Fluorouracil can be decreased when combined with Famotidine.	
Fluorouracil	[DDI] The risk or severity of adverse effects can be increased when Allopurinol is combined with Fluorouracil. [DDI] The metabolism of Fluorouracil can be decreased when combined with Fenofibrate.	



VALIDITY TESTING & SCREENS



Specimen Validity	Range	Results	Newstar Medical Laboratories - Atlanta
	4.50 - 8.00	4.5	975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144
Specific Gravity	1.01 - 1.03	1.021	Phone: (678) 505-8016 Fax: (678) 806-7192
Urine Creatinine (mg/dL)	20.00 - 400.00	195.34	CLIA ID: 11D2145553
			Laboratory Director : Robert M David, PhD
Desert Kidney Associates Chandler		Order Code: NE22-0007288	
Mashood Qadri		Sample Type: Urine	
: 22040700033		Collected: 04/06/2022	
atus: FINAL		Received: 2022-04-07T14:19:03.500702	
		Reported: 04/13/2022	

ANTICONVULSANT	Gabapentin	1000	> 50000
[DDI] Verapamil may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.			
STATIN	Atorvastatin	10	80.21
[DDI] The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibric acid is combined with Atorvastatin.			
[DDI] The metabolism of Atorvastatin can be decreased when combined with Hydralazine.			
[DDI] The metabolism of Atorvastatin can be decreased when combined with Clopidogrel.			
[DDI] The serum concentration of Verapamil can be increased when it is combined with Atorvastatin.			
[DDI] The metabolism of Fluorouracil can be decreased when combined with Atorvastatin.			
ANTIDIABETIC	Sitagliptin	50	> 2500
[DDI] The metabolism of Sitagliptin can be decreased when combined with Atorvastatin.			
[DDI] The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Sitagliptin.			
[DDI] The excretion of Sitagliptin can be decreased when combined with Salicylic acid.			
[DDI] The therapeutic efficacy of Sitagliptin can be increased when used in combination with Tamsulosin.			
[DDI] Sitagliptin may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.			
[DDI] The therapeutic efficacy of Sitagliptin can be increased when used in combination with Carvedilol.			
[DDI] Sitagliptin may decrease the excretion rate of Hydralazine which could result in a higher serum level.			
[DDI] The metabolism of Sitagliptin can be decreased when combined with Clopidogrel.			
[DDI] The metabolism of Sitagliptin can be decreased when combined with Verapamil.			
[DDI] Allopurinol may decrease the excretion rate of Sitagliptin which could result in a higher serum level.			
[DDI] The excretion of Sitagliptin can be decreased when combined with Famotidine.			
[DDI] The metabolism of Fluorouracil can be decreased when combined with Sitagliptin.			
ANTICOAGULANT	Carboxyclopidogrel	50	> 2500
Metabolite of Clopidogrel			
[DDI] The metabolism of Fluorouracil can be decreased when combined with Clopidogrel. [DDI] The metabolism of Clopidogrel can be decreased when combined with Famotidine. [DDI] The metabolism of Clopidogrel can be decreased when combined with Fenofibric acid.			
[DDI] The metabolism of Fluorouracil can be decreased when combined with Clopidogrel. [DDI] The metabolism of Clopidogrel can be decreased when combined with Famotidine. [DDI] The metabolism of Clopidogrel can be decreased when combined with Fenofibric acid.			
CARDIOVASCULAR	Norverapamil	50	> 2500
Metabolite of Verapamil			

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.



PATIENT

DEMOGRAPHICS

Patient Name: JOSEPH MONTGOMERY	Account: Desert Kidney Associates Chandler	Order Code: NE22-0007288
DOB: 04/15/1952	Provider: Mashood Qadri	Sample Type: Urine
Patient Gender: M	Accession: 22040700033	Collected: 04/06/2022
Patient Phone Number: (480) 415-8737	Report Status: FINAL	Received: 2022-04-07T14:19:03.500702
		Reported: 04/13/2022

NOT PRESCRIBED						NOT DETECTED	
Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)
Diazepam	10	Celecoxib	50	Lurasidone	25	Oxycodone	50
Diclofenac	50	Chlorpromazine	25	Meprobamate	200	Oxymorphone	50
Digoxin	10	Clonazepam	20	Metformin	500	Paroxetine	25
Dihydrocodeine	50	Clonidine	50	Methadone	100	Phenobarbital	100
Diltiazem	50	Codeine	50	Methotrexate	50	Phentermine	100
Ethyl Glucuronide	500	Cotinine	50	Metoprolol	50	Pioglitazone	50
4-Hydroxydiclofenac	50	Cyclobenzaprine	50	Mitragynine	25	Pitavastatin	10
7-Aminoclonazepam	40	Dehydroaripiprazole	20	Morphine	50	Pregabalin	150
7-Aminoflunitrazepam	40	Desalkylflurazepam	40	Mycophenolic acid	50	Propranolol	50
9-Hydroxyrisperidone	10	Desipramine	50	Naloxone	10	Protriptyline	50
a-Hydroxymidazolam	30	Dextrophan	25	Naltrexone	10	Pseudoephedrine	50
a-Hydroxytriazolam	30	Donepezil	50	Naproxen	100	Quetiapine	50
alpha-Hydroxyalprazolam	30	Doxepin	30	N-Desmethylicitalopram	50	Risperidone	10
Alprazolam	30	EDDP	100	N-Desmethyloclozapine	25	Ritalinic Acid	50
Amitriptyline	50	Ethyl Sulfate	200	N-Desmethylmirtazapine	25	Rivaroxaban	50
Amlodipine	25	Fentanyl	2	N-Desmethyloanzapine	25	Rosuvastatin	20
Amphetamine	200	Fluoxetine	25	N-Desmethyltapentadol	50	Sertraline	50
Apixaban	25	Furosemide	50	Norbuprenorphine	30	Sufentanil	5
Aripiprazole	20	Glyburide	10	Nordiazepam	40	Sumatriptan	50
Atenolol	50	Haloperidol	25	Norfentanyl	8	Tapentadol	50
Atomoxetine	50	Hydrochlorothiazide	50	Norhydrocodone	50	Temazepam	40
Baclofen	50	Hydrocodone	50	Norketamine	10	Topiramate	50
Buprenorphine	10	Hydromorphone	50	Normeperidine	100	Tramadol	100
Buspirone	50	Hydroxybupropion	50	Noroxycodone	50	Trazodone	50
Butalbital	100	Imipramine	50	Norpropoxyphene	100	Valsartan	50
Carbamazepine	50	Indomethacin	50	Nortriptyline	50	Venlafaxine	100
Carbamazepine Epoxide	50	Irbesartan	50	O-Desmethyltramadol	100	Warfarin	10
Carboxybuprofen	400	Levetiracetam	50	O-Desmethylvenlafaxine	100	Zaleplon	10
Carboxyzolpidem	50	Lisinopril	50	Olanzapine	25	Ziprasidone	25
Carisoprodol	100	Lorazepam	40	Oxazepam	40	Zolmitriptan	50

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.